

## UPDATE

FURTHER A\$5 MILLION CONVERTIBLE NOTE SIGNED  
PRE-IPO OFFER REMAINING OPEN UNTIL 14 DECEMBER 2018


### Company Overview

Elevate Australasia Pty Ltd (“Elevate” or “Company”) provides integrative healthcare services and programs to individuals through its wholly-owned multi-disciplinary clinics and in the workplace. The Company has provided corporate programs since 2007 with the first Sydney clinic established in 2010. Elevate currently operates 18 clinics in Queensland, New South Wales and Victoria, and has binding term sheets to acquire a further 9 clinics, healthcare businesses and a private hospital by IPO. The Company plans to own and operate 50 clinics by 2020. At IPO, Elevate will be fully owned and operated by the proposed ASX listing entity, Integrative Healthcare Limited.

### Offer overview

Industry sector	Healthcare
Company status	IPO planned for early 2019
Pre-IPO Offer	A\$3 million raised and A\$5 million signed in Convertible Notes. Offer remaining open until 14 December 2018
Conversion Price	20% discount to IPO price (20% premium to face value of the notes)

### Proforma Financials



Note: The proforma financials are provided by the Company and subject to assumptions.

### Growth strategy

#### China

Elevate plans to develop medical tourism from China to Australia by stages.

- Stage 1 - selecting partners in Australia and China to manage marketing, promotion, engagement of clients, and tourism-related matters;
- Stage 2 - selecting a partner and a location for a medical clinic in China.

#### Australia

The focus is on expansion of the clinic network and organic growth:

- The healthcare industry is highly fragmented;
- Deal flow is established and M&A procedures are in place;
- Expanded clinic network provides economies of scale; and
- Expanded clinic network provides larger capacity to offer medical tourism services.

### Use of Pre-IPO funds

- Contribute to the initial cash component of the acquisition of further 9 clinics, and expand services;
- Scale up operations in anticipation of the Listing and integration of acquisitions; and
- General working capital purposes.

### Upcoming IPO

Prospectus Offer

Up to A\$15 million

Use of Funds

To execute clinic expansion and strategic plan in Australia, develop medical tourism programs in Asia Pacific and Middle East.

## Market Overview


The Australian healthcare sector is valued at more than \$170.4 billion and is growing rapidly. Australia spends more on health (as a proportion of its gross domestic product) than the OECD average - 9.7% compared with 9.1% and health expenditure per Australian was A\$7,096 in 2015-16, up from A\$6,846 the previous year.

Australia has a high health status compared to other countries. Notably:

- The life expectancy of Australians (82.2 years) is the sixth highest in the OECD;
- Australia's breast and colorectal cancer survival rate ranks amongst the best in the OECD.
- Australia has one of the lowest rates of tobacco consumption (12.8%)

China has one of the largest markets for healthcare globally. The market is increasing rapidly as a number of demographic, political, social and economic factors drive increased expenditure on healthcare products and services. These factors include:

- Aging population
- Increased coverage of health insurance
- Increased incidence of chronic diseases
- Growing disposable income
- Strong support by government




## Medical Tourism

Medical tourism is one kind of health travel where the traveler visits tourist sites as well as undergoes health and medical checks, diagnostics and procedures.

The main reasons why people choose a destination outside their country of origin for medical tourism are:

- quality of healthcare;
- unavailability of services, drugs and surgery methods in the country of origin;
- long waiting lists associated with appropriate medical treatment;
- ability to remain anonymous and maintain privacy overseas;
- cost savings;
- interest in the culture of the destination in terms of language, food and religion;
- geographical proximity; and
- the added benefit of a holiday.

Because of existing relationships, the Company will initially focus on medical tourism from China. The numbers of Chinese tourists to Australia have been increasing rapidly for the past 10 years. In 2012, tourists from China were the third largest group but by 2016, China was the largest tourist group to visit Australia.



## Disclaimer

The Document is prepared by BlueMount Capital (Sydney) Pty Ltd (BlueMount) and Elevate Australasia Pty Ltd (Elevate or Company). The provision of this Document is not a representation to you or any other person that an offer of securities will be made and does not constitute an advertisement of an offer or proposed offer of securities. If any such offer is made, it will be made under a prospectus lodged with the Australian Securities and Investments Commission (ASIC). Anyone wishing to acquire securities will need to complete an application form that will be attached to, or will accompany, the prospectus. The information presented in this Document may have content that is materially different from that in the prospectus and may be presented in a materially different way. This Document is a summary only. It is not a prospectus and does not contain all of the information which would be required to be disclosed in a prospectus. Elevate reserves the right to alter the information contained in this Document. This Document is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in Elevate and neither this Document nor any of its content forms the basis of any contract or commitment.

Ross McDowall  
Director

Phone: +61 417 481 519

Email: ross.mcdowall@bluemountcapital.com

Eric Sun (Mandarin)  
Director

Phone: +61 413 255 516

Email: eric.sun@bluemountcapital.com

Len McDowall  
Managing Director

Phone: +61 418 673 066

Email: len.mcdowall@bluemountcapital.com